Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

(2015) Michelle L. Churchman et al.   CANCER CELL

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) N. Daver et al.   HAEMATOLOGICA

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

(2015) Elias Jabbour et al.   LANCET ONCOLOGY

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) N. Daver et al.   HAEMATOLOGICA

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

(2013) A. van der Veer et al.   BLOOD

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

(2013) M. Wetzler et al.   HAEMATOLOGICA

Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros

(2013) Hilde Schjerven et al.   NATURE IMMUNOLOGY

Four-channel asymmetric Real-Time PCR hybridization probe assay: A rapid pre-screening method for critical BCR-ABL kinase domain mutations

(2012) Jordi Martinez-Serra et al.   CLINICAL BIOCHEMISTRY

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

(2012) H Pfeifer et al.   LEUKEMIA

Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF

(2011) N. Nishimoto et al.   BLOOD

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2011) R. Foa et al.   BLOOD

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

(2010) F. Ravandi et al.   BLOOD

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

(2010) S. Soverini et al.   HAEMATOLOGICA

Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia

(2010) C Virely et al.   LEUKEMIA

IKZF1(Ikaros) Deletions inBCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

(2009) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

(2008) T. Burmeister et al.   BLOOD

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

(2008) Dan Jones et al.   CANCER

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

(2008) Charles G. Mullighan et al.   NATURE